Abstract:Drug molecules exist as complexed with serum proteins such as human serum albumin (HSA) and/or unbound free form in the blood circulation. Drugs can be effective only when they are free. Thus, it is important to understand aspects that are important for interaction between drugs and interacting proteins. In this study, interactions among 2990 FDA approved drugs and HSA were computational analyzed to unravel principles that are critical for drug‐HSA interactions. Docking results showed that drugs have higher affinity toward cavity‐1 (C1) than cavity‐2 (C2). A total of 1131 drug molecules have docking score greater than 60 while 768 molecules have docking score greater than 60 when they are docked in C2. In addition, three solvent channels have potential to direct solvent to C1 cavity while C2 does not have any effective channel. The post MD analyses demonstrated that drugs are making polar interactions with basic amino acids in the binding cavities. Verbscoside and ceftazidime both have stable low RMSD values throughout MD simulation with 2 Å on average in C1 cavity. The ligand RMSD shows less stability for verbscoside, which is around 4 Å when it is in complex with HSA in C1. The individual contribution of the residues K192, K196, R215, and R254 to ceftazidime are −1.92 ± 0.18, −3.09 ± 0.09, −2.17 ± 0.17, and − 2.32 ± 0.098, respectively. These residues contribute the binding energy of the verbscoside by −6.06 ± 0.08, −2.10 ± 0.06, and − 1.57 ± 0.03 kcal/mol individually in C1 cavity. C2 is making polar interactions with drug via R469, K472, and K488 residues and their contribution to the two drugs are −3.13 ± 0.21 kcal/mol for R469, −1.94 ± 0.18 kcal/mol for K472, and −1.96 ± 0.11 kcal/mol for K488 to total binding energy of ceftazidime. The binding energy of verbscoside is 57.17 ± 7.00 kcal/mol and Arg‐407 has the highest contribution this bind energy individually with −4.29 ± 0.12 kcal/mol. Drugs with hydrogen bond donor/acceptor chemical adducts such as verbscoside involve higher hydrogen bond formation in C1 pocket. Ceftazidime makes interaction with HSA toward hydrophobic residues, L384, L404, L487, and L488 in the C2 cavity.

Determination of Binding Constants for Basic Drugs with Serum Albumin by Affinity Capillary Electrophoresis with the Partial Filling Technique

Evaluation of Molecular Binding Modes on Site Ii of Human Serum Albumin

Results of Molecular Docking As Descriptors to Predict Human Serum Albumin Binding Affinity.

Study on interaction between ampicillin antibody and detection interfering proteins by computer aided protein-protein docking for biosensor interesting

Structural Basis of the Drug-binding Specificity of Human Serum Albumin

Human serum albumin immobilized on magnetizable beads: A rapid method for compound HSA binding study

Binding Interaction Between Zinc Ion and Human Serum Albumin Using Affinity Capillary Electrophoresis

Estimation of Binding Constants of Receptors and Ligands by Affinity Capillary Electrophoresis.

Protein binding study of acid drug N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine in human plasma albumin solution by high performance capillaryelectrophoresis frontal analysis

Identification and Characterization of a Single High-Affinity Fatty Acid Binding Site in Human Serum Albumin.

Mapping the Distribution and Affinities of Ligand Interaction Sites on Human Serum Albumin

Investigation of steric hindrance effect on the interactions between four alkaloids and HSA by isothermal titration calorimetry and molecular docking

[Binding Mechanism of Traditional Chinese Medicine Active Component 5-Hydroxymethyl-furfural and HSA or BSA].

Analysis of conformational change of human serum albumin using chiral capillary electrophoresis.

Probing the intermolecular interactions into serum albumin and anthraquinone systems: a spectroscopic and docking approach

Computational Analysis of Interactions Between Drugs and Human Serum Albumin

Enantiomeric Separation of Basic Drugs with Partially Filled Serum Albumin as Chiral Selector in Capillary Electrophoresis

A method for rapid screening of interactions of pharmacologically active compounds with albumin

Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation

Multi-spectroscopic and molecular docking studies of human serum albumin interactions with sulfametoxydiazine and sulfamonomethoxine.

Structural Basis of Drug Recognition by Human Serum Albumin